Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

• Assessment of patients with adverse events [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
  To determine the safety of 2 intravenous injections of autologous TAA-specific cytotoxic T-lymphocytes (CTL) in patients with Hodgkin's or non-Hodgkin's lymphoma.
  
  

• Obtain information on the expansion, persistence and anti-tumor effects of the adoptively-transferred TAA-specific CTL's [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  Information on the expansion, persistence and anti-tumor effects of the adoptively transferred tumor-specific CTL will be analyzed for the immunological parameters based on multimer analysis, intracellular cytokine staining and ELIspot assays to assess the frequency of cells secreting γ-IFN using the descriptive statistics such as mean, median, standard deviation at each time point.
  
  
• Assessment of increasing the spectrum of epitopes/antigens [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  To determine whether CTL infusions increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).
  
  

The patient will give blood to make TAA specific cytotoxic T cells in the lab. These cells will be grown and frozen. The time from the collection of the blood to make the T cells to when the cells are given back to the patient is about 1 to 2 months.

The cells will then be injected by IV into the patient over 10 minutes. Initially, two doses of T cells will be given two weeks apart. The patient may be eligible to receive up to six additional doses of the T cells at 6-8 week intervals. All of the treatments will be given by the Center for Cell and Gene Therapy at the Methodist Hospital or Texas Children's Hospital.

There are 2 stages of this study: an antigen-escalation phase and a dose-escalation stage.

The antigen-Escalation phase will be first. Patients will receive TAA-specific T cells targeting first 1 and then 2 TAAs. Once this schedule proves safe, the next group of patients will receive TAA-specific T cells targeting first 2 and then 3 TAAs. This process will continue until all 4 levels are studied. This means that the final cohort of patients will receive TAA-specific T cells targeting first 4 and then 5 TAAs. If the side effects are too severe, the number of TAAs being targeted will be lowered or the T cell injections will be stopped.

After the antigen escalation phase the dose escalation phase will begin. Patients will be started on the lowest dose (1 of 4 different levels) of T cells. Once that dose schedule proves safe, the next group of patients will be started at a higher dose. This process will continue until all 4 dose levels are studies. If the side effects are too severe, the dose will be lowered or the T cell injections will be stopped.

For both stages, patients will be followed after the injections up to one year from the last infusion.

Study Duration: Patients will be on study for approximately one year. If patients receive additional doses of the T cells as described above, the patient will be followed until 1 year after the last dose of T-cells.